Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 109389, 13 pages
http://dx.doi.org/10.1155/2014/109389
Research Article

Conditioned Media from Human Adipose Tissue-Derived Mesenchymal Stem Cells and Umbilical Cord-Derived Mesenchymal Stem Cells Efficiently Induced the Apoptosis and Differentiation in Human Glioma Cell Lines In Vitro

1Stem Cell Center, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
2Neurosurgery Department, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
3Department of Gynaecology and Obstetrics, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
4Cancer Center, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China

Received 6 December 2013; Revised 25 March 2014; Accepted 19 April 2014; Published 27 May 2014

Academic Editor: Mouldy Sioud

Copyright © 2014 Chao Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Wang and T. Jiang, “Understanding high grade glioma: molecular mechanism, therapy and comprehensive management,” Cancer Letters, vol. 331, no. 2, pp. 139–146, 2013. View at Google Scholar
  2. D. Bexell, A. Svensson, and J. Bengzon, “Stem cell-based therapy for malignant glioma,” Cancer Treatment Reviews, vol. 39, no. 4, pp. 358–365, 2013. View at Google Scholar
  3. M. Rahman, B. Hoh, N. Kohler, E. M. Dunbar, and G. J. Murad, “The future of glioma treatment: stem cells, nanotechnology and personalized medicine,” Future Oncology, vol. 8, no. 9, pp. 1149–1156, 2012. View at Google Scholar
  4. K. Sai, Q. Y. Yang, D. Shen, and Z. P. Chen, “Chemotherapy for gliomas in mainland China: an overview,” Oncology Letters, vol. 5, no. 5, pp. 1448–1452, 2013. View at Google Scholar
  5. D. Szczepanek, A. Marchel, M. Moskała, M. Krupa, P. Kunert, and T. Trojanowski, “Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study,” Neurologia i Neurochirurgia Polska, vol. 47, no. 2, pp. 101–108, 2013. View at Google Scholar
  6. H. M. Strik, C. Marosi, B. Kaina, and B. Neyns, “Temozolomide dosing regimens for glioma patients,” Current Neurology and Neuroscience Reports, vol. 12, no. 3, pp. 286–293, 2012. View at Google Scholar
  7. C. Scaringi, R. M. Enrici, and G. Minniti, “Combining molecular targeted agents with radiation therapy for malignant gliomas,” Journal of OncoTargets and Therapy, vol. 6, pp. 1079–1095, 2013. View at Google Scholar
  8. P. L. Mok, C. F. Leong, and S. K. Cheong, “Cellular mechanisms of emerging applications of mesenchymal stem cells,” The Malaysian Journal of Pathology, vol. 35, no. 1, pp. 17–32, 2013. View at Google Scholar
  9. V. Neirinckx, C. Coste, B. Rogister, and S. Wislet-Gendebien, “Concise review: adult mesenchymal stem cells, adult neural crest stem cells, and therapy of neurological pathologies: a state of play,” Stem Cells Translational Medicine, vol. 2, no. 4, pp. 284–296, 2013. View at Publisher · View at Google Scholar
  10. X. Y. Bak, D. H. Lam, J. Yang et al., “Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma,” Human Gene Therapy, vol. 22, no. 11, pp. 1365–1377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Kim, D.-S. Kim, C. H. Jeong et al., “CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas,” Biochemical and Biophysical Research Communications, vol. 407, no. 4, pp. 741–746, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Jiao, F. Guan, B. Yang et al., “Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1,” Neurology India, vol. 59, no. 2, pp. 241–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. A. Choi, J. Y. Lee, K.-C. Wang et al., “Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas,” European Journal of Cancer, vol. 48, no. 1, pp. 129–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Doucette, G. Rao, Y. Yang et al., “Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model,” Neoplasia, vol. 13, no. 8, pp. 716–725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Yin, J.-K. Kim, J.-H. Moon et al., “HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence,” Molecular Therapy, vol. 19, no. 6, pp. 1161–1169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. A. Park, C. H. Ryu, S. M. Kim et al., “CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas,” International Journal of Oncology, vol. 38, no. 1, pp. 97–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. A. Choi, S.-K. Hwang, K.-C. Wang et al., “Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma,” Neuro-Oncology, vol. 13, no. 1, pp. 61–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. I. A. Ho, H. C. Toh, W. H. Ng et al., “Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis,” Stem Cells, vol. 31, no. 1, pp. 146–155, 2013. View at Google Scholar
  19. L. Hu, J. Hu, J. Zhao et al., “Side-by-side comparison of the biological characteristics of human umbilical cord and adipose tissue-derived mesenchymal stem cells,” BioMed Research International, vol. 2013, Article ID 438243, 12 pages, 2013. View at Publisher · View at Google Scholar
  20. C. E. Griguer and C. R. Oliva, “Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria,” Current Pharmaceutical Design, vol. 17, no. 23, pp. 2421–2427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Gutiérrez-Fernández, B. Rodríguez-Frutos, L. Otero-Ortega, J. Ramos-Cejudo, B. Fuentes, and E. Díez-Tejedor, “Adipose tissue-derived stem cells in stroke treatment: from bench to bedside,” Discovery Medicine, vol. 16, no. 86, pp. 37–43, 2013. View at Google Scholar
  22. F. Xu, J. Shi, B. Yu, W. Ni, X. Wu, and Z. Gu, “Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro,” Oncology Reports, vol. 23, no. 6, pp. 1561–1567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. D.-S. Kim, J. H. Kim, J. Kwon Lee et al., “Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells,” Stem Cells and Development, vol. 18, no. 3, pp. 511–519, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Bexell, S. Gunnarsson, A. Tormin et al., “Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas,” Molecular Therapy, vol. 17, no. 1, pp. 183–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Kim, J. S. Woo, C. H. Jeong, C. H. Ryu, J. D. Jang, and S. S. Jeun, “Potential application of temozolomide in mesenchymal stem cell-Based TRAIL gene therapy against malignant glioma,” Stem Cells Translational Medicine, vol. 3, no. 2, pp. 172–182, 2014. View at Google Scholar
  26. S. Fei, X. Qi, S. Kedong, J. Guangchun, L. Jian, and Q. Wei, “The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 2, pp. 347–357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Kosaka, T. Ichikawa, K. Kurozumi et al., “Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma,” Cancer Gene Therapy, vol. 19, no. 8, pp. 572–578, 2012. View at Google Scholar
  28. K. Akimoto, K. Kimura, M. Nagano et al., “Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation,” Stem Cells and Development, vol. 22, no. 9, pp. 1370–1386, 2013. View at Google Scholar
  29. J. Behnan, P. Isakson, M. Joel et al., “Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression,” Stem Cells, vol. 32, no. 5, pp. 1110–123, 2013. View at Publisher · View at Google Scholar
  30. A. H. Stegh and R. A. DePinho, “Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma,” Cell Cycle, vol. 10, no. 1, pp. 33–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. B. B. Ordys, S. Launay, R. F. Deighton, J. McCulloch, and I. R. Whittle, “The role of mitochondria in glioma pathophysiology,” Molecular Neurobiology, vol. 42, no. 1, pp. 64–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Kögel, S. Fulda, and M. Mittelbronn, “Therapeutic exploitation of apoptosis and autophagy for glioblastoma,” Anti-Cancer Agents in Medicinal Chemistry, vol. 10, no. 6, pp. 438–449, 2010. View at Google Scholar · View at Scopus
  33. B. M. Alexander, N. Pinnell, P. Y. Wen, and A. D'Andrea, “Targeting DNA repair and the cell cycle in glioblastoma,” Journal of Neuro-Oncology, vol. 107, no. 3, pp. 463–477, 2012. View at Google Scholar
  34. M. C. Ku, S. A. Wolf, D. Respondek et al., “GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis,” Acta Neuropathologica, vol. 125, no. 4, pp. 609–620, 2013. View at Google Scholar
  35. V. Balik, P. Mirossay, P. Bohus, I. Sulla, L. Mirossay, and M. Sarissky, “Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy,” Cellular and Molecular Neurobiology, vol. 29, no. 6-7, pp. 845–858, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. E.-K. Noh, H. Kim, M. J. Park et al., “Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line,” Leukemia Research, vol. 34, no. 11, pp. 1501–1505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Fang, S.-J. Chen, J.-H. Tong, Z.-G. Wang, G.-Q. Chen, and Z. Chen, “Treatment of acute promyelocytic leukemia with ATRA and AS2O3: a model of molecular target-based cancer therapy,” Cancer Biology and Therapy, vol. 1, no. 6, pp. 614–620, 2002. View at Google Scholar · View at Scopus
  38. G. C. de Santis, M. D. B. Tamarozzi, R. B. Sousa et al., “Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, AS2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia,” Haematologica, vol. 92, no. 12, pp. 1615–1622, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Song, Z. Chen, C. Wu, and S. Zhao, “Abrogating HSP response augments cell death induced by AS2O3 in glioma cell lines,” Canadian Journal of Neurological Sciences, vol. 37, no. 4, pp. 504–511, 2010. View at Google Scholar · View at Scopus
  40. S. He, W. Zhu, Y. Zhou et al., “Transcriptional and post-transcriptional down-regulation of cyclin D1 contributes to C6 glioma cell differentiation induced by forskolin,” Journal of Cellular Biochemistry, vol. 112, no. 9, pp. 2241–2249, 2011. View at Publisher · View at Google Scholar · View at Scopus